Profile
Sector:
HealthcareIndustry:
Medical Instruments & SuppliesCountry:
BelgiumIPO:
28 April 2021Website:
http://www.nyxoah.comNext earnings report:
08 November 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 27 Sep 2024 23:36:25 GMTDividend
Analysts recommendations
Institutional Ownership
NYXH Latest News
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), September 27, 2024 , 8.00am CET / 2.00am ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received a transparency notification as detailed below. BlackRock, Inc. On September 24, 2024, Nyxoah received a transparency notification from BlackRock, Inc. and related persons indicating that BlackRock Advisors, LLC went below the 3% threshold on September 20, 2024.
Nyxoah to Participate in Upcoming Investor Conferences Mont-Saint-Guibert, Belgium – September 5, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in three upcoming investor conferences in New York City. Olivier Taelman, Nyxoah's Chief Executive Officer, will deliver corporate updates at the Baird Global Healthcare Conference on Tuesday, September 10, 2024, at 12:15pm ET, the H.C.
Nyxoah Rings the Closing Bell at Nasdaq while Preparing for U.S. Market Launch of Innovative Sleep Apnea Device
Nyxoah S.A. (NASDAQ:NYXH ) Q2 2024 Earnings Conference Call August 6, 2024 4:30 PM ET Company Participants Mikaela Kirkwood - Corporate Communications and Investor Relations Manager Olivier Taelman - CEO Loic Moreau - CFO Conference Call Participants Suraj Kalia - Oppenheimer Edward White - H.C.
Nyxoah SA (NYXH) came out with a quarterly loss of $0.46 per share versus the Zacks Consensus Estimate of a loss of $0.45. This compares to loss of $0.49 per share a year ago.
Nyxoah to Release Second Quarter and First Half 2024 Financial Results on August 6, 2024 Mont-Saint-Guibert, Belgium – July 29, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will release financial results for the second quarter and first half 2024 on Tuesday, August 6, 2024, after market close. Company management will host a conference call to discuss financial results that day beginning at 10:30pm CET / 4:30pm ET.
Nyxoah Appoints Scott Holstine as Chief Commercial Officer Mont-Saint-Guibert, Belgium – July 15, 2024, 8:00am CET / 2:00am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced the appointment of Scott Holstine as Chief Commercial Officer. In this role, Scott will lead the commercial operations of Nyxoah enabling a successful U.S. launch.
Nyxoah Submits Fourth and Final Module in PMA Application for Genio to the US FDA Mont-Saint-Guibert (Belgium), July 1, 2024 , 8:00am CET / 2:00am ET – (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company submitted the fourth and final module of its Premarket Approval (PMA) application for Genio to the U.S. Food and Drug Administration (FDA). Genio is a different approach to hypoglossal nerve stimulation (HGNS).
Nyxoah to Participate in the Jefferies Global Healthcare Conference Mont-Saint-Guibert, Belgium – June 3, 2024, 10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company will participate in the Jefferies Global Healthcare Conference, which takes place June 5 – 6, 2024 in New York. Olivier Taelman, Nyxoah's Chief Executive Officer, will deliver a corporate presentation on Wednesday, June 5, 2024, at 7:30am ET.
REGULATED INFORMATION Publication relating to transparency notifications Mont-Saint-Guibert (Belgium), June 3, 2024, 10.05pm CET / 4.05pm ET – In accordance with article 14 of the Act of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) announces that it received four transparency notifications as detailed below. FMR LLC On May 30, 2024, Nyxoah received a transparency notification from FMR LLC following the crossing above the 3% threshold on May 28, 2024.
- 1(current)
What type of business is Nyxoah SA?
Nyxoah S.A., a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah S.A. was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
What sector is Nyxoah SA in?
Nyxoah SA is in the Healthcare sector
What industry is Nyxoah SA in?
Nyxoah SA is in the Medical Instruments & Supplies industry
What country is Nyxoah SA from?
Nyxoah SA is headquartered in Belgium
When did Nyxoah SA go public?
Nyxoah SA initial public offering (IPO) was on 28 April 2021
What is Nyxoah SA website?
https://www.nyxoah.com
Is Nyxoah SA in the S&P 500?
No, Nyxoah SA is not included in the S&P 500 index
Is Nyxoah SA in the NASDAQ 100?
No, Nyxoah SA is not included in the NASDAQ 100 index
Is Nyxoah SA in the Dow Jones?
No, Nyxoah SA is not included in the Dow Jones index
When was Nyxoah SA the previous earnings report?
No data
When does Nyxoah SA earnings report?
The next expected earnings date for Nyxoah SA is 08 November 2024